Literature DB >> 15336425

Variation in antimicrobial activity of lactoferricin-derived peptides explained by structure modelling.

Sebastien Farnaud1, Alpesh Patel, Edward W Odell, Robert W Evans.   

Abstract

Antimicrobial peptides bovine lactoferricin (LfcinB) and human lactoferricin (LfcinH) are produced from the respective lactoferrin, but are more active than their precursors. Despite sequence homology, the bovine peptide and its derivatives are more active than their human homologs. Such differences between not only the peptides and their precursor but also between the bovine and the human peptides could relate to structural differences. Upon sequence alignment of both peptides with their parental proteins, the structural differences observed between the bovine lactoferrin (BLf) and LfcinB were also found between the human lactoferrin (HLf) and the LfcinH. The helical structures in HLf are replaced by beta-strands separated by a strong turn in LfcinH suggesting an antiparallel beta-sheet structure similar to LfcinB. MIC assays with HLP-2 and BLP-2, 11-residue peptides derived from the active core of both Lfcins, against Escherichia coli, showed that the bovine derivative, BLP-2, is more active than its human homolog HLP-2. Both 3D models for HLP-2 and BLP-2 showed that the beta-strand is centred between the aromatic residues giving both side chains the same orientations. The displacement towards the N-terminus observed for the beta-strand in HLP-2, compared with its central location in BLP-2, could be less favourable to membrane interaction and therefore responsible for the decrease in activity. Such a model suggests for LfcinH a mechanism similar to the one observed for LfcinB, where the absence of long-range interaction, present in lactoferrin, destabilises the first alpha helix, as observed in solution and, upon interaction with the membrane, could result in the formation of a beta-strand, as observed in the presence of LPS. The location of the beta-strand in relation to the positive charges, seems to define the efficiency of the activity of the peptide and may explain the difference in activity obtained between HLP-2 and BLP-2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15336425     DOI: 10.1016/j.femsle.2004.07.038

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  8 in total

1.  Serine protease PrtA from Streptococcus pneumoniae plays a role in the killing of S. pneumoniae by apolactoferrin.

Authors:  Shaper Mirza; Landon Wilson; William H Benjamin; Jan Novak; Stephen Barnes; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2011-03-21       Impact factor: 3.441

2.  Transgenic cows that produce recombinant human lactoferrin in milk are not protected from experimental Escherichia coli intramammary infection.

Authors:  P Hyvönen; L Suojala; T Orro; J Haaranen; O Simola; C Røntved; S Pyörälä
Journal:  Infect Immun       Date:  2006-09-05       Impact factor: 3.441

3.  Structure-microbicidal activity relationship of synthetic fragments derived from the antibacterial alpha-helix of human lactoferrin.

Authors:  L Håversen; N Kondori; L Baltzer; L A Hanson; G T Dolphin; K Dunér; I Mattsby-Baltzer
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

4.  Antibacterial activity of synthetic peptides derived from lactoferricin against Escherichia coli ATCC 25922 and Enterococcus faecalis ATCC 29212.

Authors:  María A León-Calvijo; Aura L Leal-Castro; Giovanni A Almanzar-Reina; Jaiver E Rosas-Pérez; Javier E García-Castañeda; Zuly J Rivera-Monroy
Journal:  Biomed Res Int       Date:  2015-03-01       Impact factor: 3.411

5.  A tetrameric peptide derived from bovine lactoferricin as a potential therapeutic tool for oral squamous cell carcinoma: A preclinical model.

Authors:  Víctor Alfonso Solarte; Paulette Conget; Jean-Paul Vernot; Jaiver Eduardo Rosas; Zuly Jenny Rivera; Javier Eduardo García; Martha Ligia Arango-Rodríguez
Journal:  PLoS One       Date:  2017-03-30       Impact factor: 3.240

Review 6.  Diverse Mechanisms of Antimicrobial Activities of Lactoferrins, Lactoferricins, and Other Lactoferrin-Derived Peptides.

Authors:  Špela Gruden; Nataša Poklar Ulrih
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

7.  Lactoferrin dampens high-fructose corn syrup-induced hepatic manifestations of the metabolic syndrome in a murine model.

Authors:  Yi-Chieh Li; Chang-Chi Hsieh
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

8.  A Tetrameric Peptide Derived from Bovine Lactoferricin Exhibits Specific Cytotoxic Effects against Oral Squamous-Cell Carcinoma Cell Lines.

Authors:  Víctor A Solarte; Jaiver E Rosas; Zuly J Rivera; Martha L Arango-Rodríguez; Javier E García; Jean-Paul Vernot
Journal:  Biomed Res Int       Date:  2015-11-02       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.